I-O Drugs: Key to the Cancer Moonshot?

Checkpoint inhibitor immuno-oncology (I-O) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?

Join us for a live webinar to take a data-driven look at the key challenges facing I-O drugs including:

  • Cost and Value
  • Interpretation of clinical efficacy evidence
  • Restrictions issued by HTA agencies


Ashley Jaksa, MPH

Vice President, Data & Analytics

Context Matters